---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-026172"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:48:29.292427+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica doses first patient in Phase 2/3 stroke trial; Q3 cash $48.1M after $30M raise

## Summary
- First patient dosed in pivotal ReMEDy2 trial of DM199 for acute ischemic stroke; ~350 patients planned.
- FDA granted Fast Track Designation for DM199 in AIS; protocol amendment adds stroke recurrence as primary endpoint.
- Completed $30M private placement in Sept 2021; cash, equivalents and marketable securities $48.1M at Sept 30.
- Q3 2021 R&D expenses $2.3M (vs $2.2M Q3 2020); net cash used in ops $9.4M for 9 months.
- Additional REDUX Phase 2 data in IgAN showed >30% reduction in albuminuria at ASN Kidney Week.

## SEC filing metadata
- accession: 0001437749-21-026172
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774921026172/0001437749-21-026172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774921026172/dmtp20211110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-026172
- JSON: https://secwatch.observer/filing/0001437749-21-026172.json
- Plain text: https://secwatch.observer/filing/0001437749-21-026172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.